As the world continues to face chronic pain disorder burden, efficient and relieving topical pain relief becomes paramount for managing this condition. Given this, global demand for topical pain relief is anticipated to surge at a 5.6% CAGR through 2034.
The market value is projected to increase from US$ 11,061.3 million in 2024 to US$ 18,994.4 million by 2034. The market was valued at US$ 10,513.1 million in 2023 and is anticipated to exhibit a Y-o-Y growth of 5.2% in 2024.
| Attributes | Market Insights |
|---|---|
| Base Value, 2023 | US$ 10,513.1 million |
| Global Topical Pain Relief Market Size (2024) | US$ 11,061.3 million |
| Market Forecast for Topical Pain Relief Industry (2034) | US$ 18,994.4 million |
| Value-based CAGR (2024 to 2034) | 5.6% |
Rising aging population is surging the demand for pain management solutions, particularly topical pain relief medications for chronic pain problems such as arthritis, back pain, and muscle pain.
These products offer convenience and relief, making them highly preferred over invasive ones. Continuous research & development efforts by leading manufacturers can improve the effectiveness and safety of these pain relief solutions.
Following the COVID-19 pandemic, people are adopting healthy habits and engaging in sports activities, which are prone to acute injuries. Sprays are used to relax suffering in these sports.
A competitive industry is created by the various topical pain treatment medications offered by pharmaceutical and healthcare companies. Regulatory licenses and safety regulations are essential in the market as they influence product accessibility and customer confidence.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The market recorded a historical CAGR of 4.0% from 2019 to 2023. Historically, pain relief medications have been developed through ongoing research and development, focusing on novel formulations, optimizing active component bioavailability, and improving delivery systems.
The incidence of chronic and neuropathic pain rises with age, with adults being more susceptible to these conditions. Chronic and neuropathic pain are increasingly prevalent due to health conditions like diabetes, cancer, and autoimmune diseases. The conditions necessitate healthcare providers to monitor these rates and provide appropriate treatment options.
The growing prevalence of neuropathic and chronic pain is projected to fuel growth of the market, with a focus on non-opioid medications and the development of safer, more effective pain management therapies.
Reimbursement policies by governments are set to encourage healthcare professionals to offer non-opioid topical therapies in palliative care plans.
Consumers seek natural and organic alternatives in healthcare and personal care, leading to the development of topical pain treatment medicines containing natural components. Leading companies and manufacturers are investing in research & development to produce unique formulations for precise and efficient pain treatment.
Technological developments, such as transdermal medication delivery methods, enhance active chemical absorption, providing reliable and long-lasting pain relief.
The market is further projected to grow due to rising geriatric population, high prevalence of chronic diseases, increased sports activity, and accidental injuries. The safety and efficacy of these treatments are projected to push manufacturers to develop unconventional products, such as one-shot technology in sprays, to enhance treatment efficacy.
Principal Consultant
The market is undergoing a shift toward non-opioid alternatives due to increased public awareness of opioid risks and the need for safe alternatives. Due to the severity of abusive opioids and their misuse, physicians have reduced their prescriptions for pain management, which has decreased their sales globally.
According to the International Association for the Study of Pain (IASP), around 20 to 30% of opioids prescribed for chronic pain are being misused. It also mentions that up to 10% of the total opioid consumers are addicted to it. The growing incidence of opioid abuse is set to hinder growth in the market.
The table below highlights the anticipated growth rates of leading countries. Among these, China is projected to remain a highly lucrative market for topical pain relief, exhibiting a CAGR of 8.4%. The United States and India are anticipated to follow with CAGRs of 3.8% and 7.1%, respectively.
| Countries | Value CAGR (2024 to 2034) |
|---|---|
| United States | 3.8% |
| Germany | 3.1% |
| United Kingdom | 2.6% |
| Japan | 2.4% |
| China | 8.4% |
| India | 7.1% |
Manufacturers in the United States often prioritize natural and organic ingredients in their product formulations to satisfy the increasing demand for wellness-focused, clean-label products. Public education campaigns by NGOs and governments have been running to inform people about the benefits of topical painkillers and how to use them safely & appropriately.
CBD, a potent analgesic and anti-inflammatory, is gaining traction as a natural substitute for pain relief medicines in the United States. This trend is propelled by pharmacies, drugstores, supermarkets, and internet platforms offering topical pain relief solutions, with direct-to-consumer sales channels emerging due to convenience.
China's growth in the topical pain relief market is notable, with a surge in commercial development through novel product approvals. The country's robust investment in research & development, coupled with a burgeoning healthcare sector, has propelled the demand for topical pain relief.
Growing awareness and adoption of topical pain relief products in various applications contribute to China's flourishing market, positioning the country as a key player in the global landscape.
The demand for over-the-counter pain relievers in China is growing due to the rise in arthritis, diabetic neuropathy, and joint pain, as well as the increasing elderly population. Leading companies in China are introducing new pain relief components, delivery systems, and formulations to meet consumer needs.
India is making significant strides in the market. It is projected to showcase positive growth trends by 2034. Chronic pain conditions are on the rise in India due to the growing elderly population and changing lifestyles characterized by more stress & sedentary behavior.
A sizeable section of the populace suffers from conditions such as joint pain, arthritis, and back pain, fueling demand for topical pain relief in India. For instance, millions of Indians have arthritis, with osteoarthritis being the most common type, especially in older adults.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The table below signifies leading sub-categories under drug class, formulations, and packaging type categories in the market. The non-opioids segment is projected to surge at a CAGR of 4.7% in the evaluation period. Under the formulation category, the cream and ointment segment is projected to rise at a CAGR of 3.0% by 2034.
| Segment | Value CAGR (2024 to 2034) |
|---|---|
| Tubes (Packaging Type) | 3.3% |
| Hospitals (Distribution Channel) | 7.0% |
| Creams and Ointments (Formulation) | 3.0% |
| Non-opioids (Drug Class) | 4.7% |
The non-opioid segment dominated the global market with a 72.5% share in 2023 and is projected to continue experiencing high growth throughout the forecast period. Topical pain medications without opioids are considered safer due to their lower risk of addiction, dependence, and overdose compared to opioid-based alternatives.
Healthcare professionals prefer non-opioid formulations for the treatment of mild to moderate pain, particularly for chronic conditions that call for long-term use. Compared to oral medications, non-opioid topical pain relievers usually have fewer systemic side effects, fueling the segment’s growth.
Cream formulations are widely utilized in topical pain management because of their rapid skin absorption, simplicity of administration, and capacity to deliver targeted comfort.
Various active ingredients meant to lessen pain and suffering are frequently used in pain relief creams. Manufacturers often carry out clinical trials to demonstrate the efficacy and safety of their cream formulations, further propelling demand.
The tube segment dominated the global market with a 35.7% share in 2023 and is projected to continue experiencing substantial growth by 2034. Since tubes often have a sealed nozzle or cap that helps keep product integrity and avoid contamination, they offer a hygienic application method.
Tubes are also essential for applying topical pain relief medications directly to the affected area, making them easy to use and effective for skin contact. The easy dispensing mechanism of tubes makes the product's smooth and even application possible.
Leading topical pain relief product manufacturers prioritize product innovation and launches to meet high demand and broaden their global consumer base through unique formulations & delivery methods. Manufacturers in the pharmaceutical sector also apply for authorization from regulatory organizations to stay relevant in the market.
For instance
The global market is set to reach US$ 18,994.4 million by 2034.
Demand for topical pain relief is slated to rise at a 5.6% CAGR by 2034.
The non-opioids segment is set to lead the global market in 2024.
The market is projected to reach US$ 11,061.3 million in 2024.
The United States accounted for around 33.5% share of the global market in 2023.
Johnson & Johnson, Pfizer Inc., and Novartis AG are the key players.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply Side Trends 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 2.3. Inclusions and Exclusions 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Class Innovation / Development Trends 4. Key Success Factors 4.1. Drug Class Adoption/ Usage Analysis 4.2. Regulatory Scenario 4.3. PESTLE Analysis 4.4. Porter’s Analysis 4.5. Value Chain Analysis 5. Market Background 5.1. Macro-Economic Factors 5.1.1. Global GDP Growth Outlook 5.1.2. Global Healthcare Expenditure Outlook 5.1.3. Global Painkillers Market Outlook 5.2. Forecast Factors - Relevance & Impact 5.2.1. Rise in Government Funding for Research and Development 5.2.2. Incidence of Pain 5.2.3. Patent Expiration of Novel Pain Management Drugs (Opioids) 5.2.4. Average Annual Spending on Pain Management Drugs 5.2.5. Awareness for Medications 5.2.6. Regulatory Approvals 5.2.7. Popularity of Generic Drug Class 5.2.8. Market Consolidation Activities 5.3. Market Dynamics 5.3.1. Drivers 5.3.2. Restraints 5.3.3. Opportunity Analysis 6. Global Market Demand (in Value or Size in US$ million) Analysis 2019 to 2023 and Forecast, 2024 to 2034 6.1. Historical Market size (US$ million) Trend Analysis, 2019 to 2023 6.2. Current and Future Market Size (US$ million) and Forecast Projections, 2024 to 2034 6.2.1. Y-o-Y Growth Trend Analysis 6.2.2. Absolute $ Opportunity Analysis 7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Drug Class 7.1. Introduction / Key Findings 7.2. Historical Market Size (US$ million) Trend Analysis By Drug Class, 2019 to 2023 7.3. Current and Future Market Size (US$ million) Analysis and Forecast By Drug Class, 2024 to 2034 7.3.1. Opioids 7.3.1.1. Hydrocodone 7.3.1.2. Oxycodone 7.3.1.3. Morphine 7.3.1.4. Fentanyl 7.3.1.5. Others 7.3.2. Non-opioids 7.3.2.1. Ibuprofen 7.3.2.2. Naproxen 7.3.2.3. Diclofenac 7.3.2.4. Acetaminophen 7.3.2.5. Lidocaine 7.3.2.6. Capsaicin 7.3.2.7. Corticosteroids 7.3.2.8. Prednisone 7.3.2.9. Dexamethasone 7.3.2.10. Others 7.4. Market Attractiveness Analysis By Drug Class 8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Formulation 8.1. Introduction / Key Findings 8.2. Historical Market Size (US$ million) Trend Analysis By Formulation, 2019 to 2023 8.3. Current and Future Market Size (US$ million) Analysis and Forecast By Formulation, 2024 to 2034 8.3.1. Creams and Ointments 8.3.2. Gels 8.3.3. Liquid/Oil 8.3.4. Patch 8.3.5. Sprays 8.3.6. Others 8.4. Market Attractiveness Analysis By Formulation 9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Packaging Type 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ million) Trend Analysis By Packaging Type, 2019 to 2023 9.3. Current and Future Market Size (US$ million) Analysis and Forecast By Packaging Type, 2024 to 2034 9.3.1. Tubes 9.3.1.1. Creams and Ointments 9.3.1.2. Gels 9.3.2. Containers & Jars 9.3.2.1. Creams and Ointments 9.3.2.2. Gels 9.3.3. Aerosol Containers 9.3.3.1. Sprays 9.3.4. Dermal Patches 9.3.4.1. Patches 9.3.5. Roll On Bottles 9.3.5.1. Liquid/Oil 9.4. Market Attractiveness Analysis By Packaging Type 10. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Distribution Channel 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ million) Trend Analysis By Distribution Channel, 2019 to 2023 10.3. Current and Future Market Size (US$ million) Analysis and Forecast By Distribution Channel, 2024 to 2034 10.3.1. Hospitals 10.3.2. Clinics 10.3.3. Retail Pharmacy Stores 10.3.4. Drug Stores 10.3.5. Online Pharmacy Stores 10.3.6. Others 10.4. Market Attractiveness Analysis By Distribution Channel 11. Global Market : Cross Sectional Analysis - Drug Class Vs Distribution Channel 11.1. Historical Market Size (US$ million) By Drug Class Vs Distribution Channel, 2019 to 2023 11.2. Current and Future Market Size (US$ million) Analysis and Forecast by Drug Class Vs Distribution Channel, 2024 to 2034 11.2.1. Opioids 11.2.1.1. Hospitals 11.2.1.2. Clinics 11.2.1.3. Retail Pharmacy Stores 11.2.1.4. Drug Stores 11.2.1.5. Online Pharmacy Stores 11.2.1.6. Others 11.2.2. Non-Opioids 11.2.2.1. Hospitals 11.2.2.2. Clinics 11.2.2.3. Retail Pharmacy Stores 11.2.2.4. Drug Stores 11.2.2.5. Online Pharmacy Stores 11.2.2.6. Others 12. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Region 12.1. Introduction 12.2. Historical Market Size (US$ million) Trend Analysis and By Region, 2019 to 2023 12.3. Current and Future Market Size (US$ million) Analysis and Forecast By Region, 2024 to 2034 12.3.1. North America 12.3.2. Latin America 12.3.3. East Asia 12.3.4. South Asia & Pacific 12.3.5. Western Europe 12.3.6. Eastern Europe 12.3.7. Middle East and Africa 12.4. Market Attractiveness Analysis By Region 12.5. Key Market Trends, By Region 13. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034 13.1. Introduction 13.2. Historical Market Size (US$ million) Trend Analysis By Market Taxonomy, 2019 to 2023 13.3. Current and Future Market Size (US$ million) Analysis and Forecast By Market Taxonomy, 2024 to 2034 13.3.1. By Country 13.3.1.1. United States 13.3.1.2. Canada 13.3.1.3. Mexico 13.3.2. By Drug Class 13.3.3. By Formulation 13.3.4. By Packaging Type 13.3.5. By Distribution Channel 13.4. Market Attractiveness Analysis 13.4.1. By Country 13.4.2. By Drug Class 13.4.3. By Formulation 13.4.4. By Packaging Type 13.4.5. By Distribution Channel 13.5. Drivers and Restraints - Impact Analysis 13.6. Country Level Analysis & Forecast 13.6.1. United States Market Analysis 13.6.1.1. .Introduction 13.6.1.2. Market Analysis and Forecast by Market Taxonomy 13.6.1.2.1. By Drug Class 13.6.1.2.2. By Formulation 13.6.1.2.3. By Packaging Type 13.6.1.2.4. By Distribution Channel 13.6.2. Canada Market Analysis 13.6.2.1. Introduction 13.6.2.2. Market Analysis and Forecast by Market Taxonomy 13.6.2.2.1. By Drug Class 13.6.2.2.2. By Formulation 13.6.2.2.3. By Packaging Type 13.6.2.2.4. By Distribution Channel 13.6.3. Mexico Market Analysis 13.6.3.1. Introduction 13.6.3.2. Market Analysis and Forecast by Market Taxonomy 13.6.3.2.1. By Drug Class 13.6.3.2.2. By Formulation 13.6.3.2.3. By Packaging Type 13.6.3.2.4. By Distribution Channel 14. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034 14.1. Introduction 14.2. Historical Market Size (US$ million) Trend Analysis By Market Taxonomy, 2019 to 2023 14.3. Current and Future Market Size (US$ million) Analysis and Forecast By Market Taxonomy, 2024 to 2034 14.3.1. By Country 14.3.1.1. Brazil 14.3.1.2. Chile 14.3.1.3. Rest of Latin America 14.3.2. By Drug Class 14.3.3. By Formulation 14.3.4. By Packaging Type 14.3.5. By Distribution Channel 14.4. Market Attractiveness Analysis 14.4.1. By Country 14.4.2. By Drug Class 14.4.3. By Formulation 14.4.4. By Packaging Type 14.4.5. By Distribution Channel 14.5. Drivers and Restraints - Impact Analysis 14.6. Country Level Analysis & Forecast 14.6.1. Brazil Market Analysis 14.6.1.1. Introduction 14.6.1.2. Market Analysis and Forecast by Market Taxonomy 14.6.1.2.1. By Drug Class 14.6.1.2.2. By Formulation 14.6.1.2.3. By Packaging Type 14.6.1.2.4. By Distribution Channel 14.6.2. Chile Market Analysis 14.6.2.1. Introduction 14.6.2.2. Market Analysis and Forecast by Market Taxonomy 14.6.2.2.1. By Drug Class 14.6.2.2.2. By Formulation 14.6.2.2.3. By Packaging Type 14.6.2.2.4. By Distribution Channel 15. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034 15.1. Introduction 15.2. Historical Market Size (US$ million) Trend Analysis By Market Taxonomy, 2019 to 2023 15.3. Current and Future Market Size (US$ million) Analysis and Forecast By Market Taxonomy, 2024 to 2034 15.3.1. By Country 15.3.1.1. China 15.3.1.2. Japan 15.3.1.3. South Korea 15.3.2. By Drug Class 15.3.3. By Formulation 15.3.4. By Packaging Type 15.3.5. By Distribution Channel 15.4. Market Attractiveness Analysis 15.4.1. By Country 15.4.2. By Drug Class 15.4.3. By Formulation 15.4.4. By Packaging Type 15.4.5. By Distribution Channel 15.5. Drivers and Restraints - Impact Analysis 15.6. Country Level Analysis & Forecast 15.6.1. China Market Analysis 15.6.1.1. Introduction 15.6.1.2. Market Analysis and Forecast by Market Taxonomy 15.6.1.2.1. By Drug Class 15.6.1.2.2. By Formulation 15.6.1.2.3. By Packaging Type 15.6.1.2.4. By Distribution Channel 15.6.2. Japan Market Analysis 15.6.2.1. Introduction 15.6.2.2. Market Analysis and Forecast by Market Taxonomy 15.6.2.2.1. By Drug Class 15.6.2.2.2. By Formulation 15.6.2.2.3. By Packaging Type 15.6.2.2.4. By Distribution Channel 15.6.3. South Korea Market Analysis 15.6.3.1. Introduction 15.6.3.2. Market Analysis and Forecast by Market Taxonomy 15.6.3.2.1. By Drug Class 15.6.3.2.2. By Formulation 15.6.3.2.3. By Packaging Type 15.6.3.2.4. By Distribution Channel 16. South Asia and Pacific Market Analysis 2019 to 2023 and Forecast 2024 to 2034 16.1. Introduction 16.2. Historical Market Size (US$ million) Trend Analysis & Forecast By Market Taxonomy, 2019 to 2023 16.3. Current and Future Market Size (US$ million) Analysis and Forecast Analysis By Market Taxonomy, 2024 to 2034 16.3.1. By Country 16.3.1.1. India 16.3.1.2. ASEAN Countries 16.3.1.3. Australia & New Zealand 16.3.1.4. Rest of South Asia & Pacific 16.3.2. By Drug Class 16.3.3. By Formulation 16.3.4. By Packaging Type 16.3.5. By Distribution Channel 16.4. Market Attractiveness Analysis 16.4.1. By Country 16.4.2. By Drug Class 16.4.3. By Formulation 16.4.4. By Packaging Type 16.4.5. By Distribution Channel 16.5. Drivers and Restraints - Impact Analysis 16.6. Country Level Analysis & Forecast 16.6.1. India Market Analysis 16.6.1.1. Introduction 16.6.1.2. Market Analysis and Forecast by Market Taxonomy 16.6.1.2.1. By Drug Class 16.6.1.2.2. By Formulation 16.6.1.2.3. By Packaging Type 16.6.1.2.4. By Distribution Channel 16.6.2. ASEAN Countries Market Analysis 16.6.2.1. Introduction 16.6.2.2. Market Analysis and Forecast by Market Taxonomy 16.6.2.2.1. By Drug Class 16.6.2.2.2. By Formulation 16.6.2.2.3. By Packaging Type 16.6.2.2.4. By Distribution Channel 16.6.3. Australia & New Zealand Pain Relief Market Analysis 16.6.3.1. Introduction 16.6.3.2. Market Analysis and Forecast by Market Taxonomy 16.6.3.2.1. By Drug Class 16.6.3.2.2. By Formulation 16.6.3.2.3. By Packaging Type 16.6.3.2.4. By Distribution Channel 17. Western Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034 17.1. Introduction 17.2. Historical Market Size (US$ million) Trend Analysis By Market Taxonomy, 2019 to 2023 17.3. Current and Future Market Size (US$ million) Analysis and Forecast Analysis By Market Taxonomy, 2024 to 2034 17.3.1. By Country 17.3.1.1. Germany 17.3.1.2. Italy 17.3.1.3. France 17.3.1.4. United Kingdom 17.3.1.5. Spain 17.3.1.6. BENELUX 17.3.1.7. Nordic Countries 17.3.1.8. Rest of Western Europe 17.3.2. By Drug Class 17.3.3. By Formulation 17.3.4. By Packaging Type 17.3.5. By Distribution Channel 17.4. Market Attractiveness Analysis 17.4.1. By Country 17.4.2. By Drug Class 17.4.3. By Formulation 17.4.4. By Packaging Type 17.4.5. By Distribution Channel 17.5. Drivers and Restraints - Impact Analysis 17.6. Country Level Analysis & Forecast 17.6.1. Germany Market Analysis 17.6.1.1. Introduction 17.6.1.2. Market Analysis and Forecast by Market Taxonomy 17.6.1.2.1. By Drug Class 17.6.1.2.2. By Formulation 17.6.1.2.3. By Packaging Type 17.6.1.2.4. By Distribution Channel 17.6.2. Italy Market Analysis 17.6.2.1. Introduction 17.6.2.2. Market Analysis and Forecast by Market Taxonomy 17.6.2.2.1. By Drug Class 17.6.2.2.2. By Formulation 17.6.2.2.3. By Packaging Type 17.6.2.2.4. By Distribution Channel 17.6.3. France Market Analysis 17.6.3.1. Introduction 17.6.3.2. Market Analysis and Forecast by Market Taxonomy 17.6.3.2.1. By Drug Class 17.6.3.2.2. By Formulation 17.6.3.2.3. By Packaging Type 17.6.3.2.4. By Distribution Channel 17.6.4. United Kingdom Market Analysis 17.6.4.1. Introduction 17.6.4.2. Market Analysis and Forecast by Market Taxonomy 17.6.4.2.1. By Drug Class 17.6.4.2.2. By Formulation 17.6.4.2.3. By Packaging Type 17.6.4.2.4. By Distribution Channel 17.6.5. Spain Market Analysis 17.6.5.1. Introduction 17.6.5.2. Market Analysis and Forecast by Market Taxonomy 17.6.5.2.1. By Drug Class 17.6.5.2.2. By Formulation 17.6.5.2.3. By Packaging Type 17.6.5.2.4. By Distribution Channel 17.6.6. BENELUX Market Analysis 17.6.6.1. Introduction 17.6.6.2. Market Analysis and Forecast by Market Taxonomy 17.6.6.2.1. By Drug Class 17.6.6.2.2. By Formulation 17.6.6.2.3. By Packaging Type 17.6.6.2.4. By Distribution Channel 17.6.7. Nordic Countries Market Analysis 17.6.7.1. Introduction 17.6.7.2. Market Analysis and Forecast by Market Taxonomy 17.6.7.2.1. By Drug Class 17.6.7.2.2. By Formulation 17.6.7.2.3. By Packaging Type 17.6.7.2.4. By Distribution Channel 18. Eastern Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034 18.1. Introduction 18.2. Historical Market Size (US$ million) Trend Analysis By Market Taxonomy, 2019 to 2023 18.3. Current and Future Market Size (US$ million) Analysis and Forecast By Market Taxonomy, 2024 to 2034 18.3.1. By Country 18.3.1.1. Russia 18.3.1.2. Hungary 18.3.1.3. Poland 18.3.1.4. Rest of Eastern Europe 18.3.2. By Drug Class 18.3.3. By Formulation 18.3.4. By Packaging Type 18.3.5. By Distribution Channel 18.4. Market Attractiveness Analysis 18.4.1. By Drug Class 18.4.2. By Formulation 18.4.3. By Packaging Type 18.4.4. By Distribution Channel 18.5. Drivers and Restraints - Impact Analysis 18.6. Country Level Analysis & Forecast 18.6.1. Russia Market Analysis 18.6.1.1. Introduction 18.6.1.2. Market Analysis and Forecast by Market Taxonomy 18.6.1.2.1. By Drug Class 18.6.1.2.2. By Formulation 18.6.1.2.3. By Packaging Type 18.6.1.2.4. By Distribution Channel 18.6.2. Hungary Market Analysis 18.6.2.1. Introduction 18.6.2.2. Market Analysis and Forecast by Market Taxonomy 18.6.2.2.1. By Drug Class 18.6.2.2.2. By Formulation 18.6.2.2.3. By Packaging Type 18.6.2.2.4. By Distribution Channel 18.6.3. Poland Market Analysis 18.6.3.1. Introduction 18.6.3.2. Market Analysis and Forecast by Market Taxonomy 18.6.3.2.1. By Drug Class 18.6.3.2.2. By Formulation 18.6.3.2.3. By Packaging Type 18.6.3.2.4. By Distribution Channel 19. Middle East and Africa Market Analysis 2019 to 2023 and Forecast 2024 to 2034 19.1. Introduction 19.2. Historical Market Size (US$ million) Trend Analysis & Forecast By Market Taxonomy, 2019 to 2023 19.3. Current and Future Market Size (US$ million) Analysis and Forecast By Market Taxonomy, 2024 to 2034 19.3.1. By Country 19.3.1.1. Saudi Arabia 19.3.1.2. Türkiye 19.3.1.3. South Africa 19.3.1.4. Other African Union 19.3.1.5. Rest of Middle East & Africa 19.3.2. By Drug Class 19.3.3. By Formulation 19.3.4. By Packaging Type 19.3.5. By Distribution Channel 19.4. Market Attractiveness Analysis 19.4.1. By Country 19.4.2. By Drug Class 19.4.3. By Formulation 19.4.4. By Packaging Type 19.4.5. By Distribution Channel 19.5. Drivers and Restraints - Impact Analysis 19.6. Country Level Analysis & Forecast 19.6.1. Saudi Arabia Market Analysis 19.6.1.1. Introduction 19.6.1.2. Market Analysis and Forecast by Market Taxonomy 19.6.1.2.1. By Drug Class 19.6.1.2.2. By Formulation 19.6.1.2.3. By Packaging Type 19.6.1.2.4. By Distribution Channel 19.6.2. Türkiye Market Analysis 19.6.2.1. Introduction 19.6.2.2. Market Analysis and Forecast by Market Taxonomy 19.6.2.2.1. By Drug Class 19.6.2.2.2. By Formulation 19.6.2.2.3. By Packaging Type 19.6.2.2.4. By Distribution Channel 19.6.3. South Africa Market Analysis 19.6.3.1. Introduction 19.6.3.2. Market Analysis and Forecast by Market Taxonomy 19.6.3.2.1. By Drug Class 19.6.3.2.2. By Formulation 19.6.3.2.3. By Packaging Type 19.6.3.2.4. By Distribution Channel 19.6.4. Other African Union Market Analysis 19.6.4.1. Introduction 19.6.4.2. Market Analysis and Forecast by Market Taxonomy 19.6.4.2.1. By Drug Class 19.6.4.2.2. By Formulation 19.6.4.2.3. By Packaging Type 19.6.4.2.4. By Distribution Channel 20. Market Structure Analysis 20.1. Market Analysis by Tier of Companies 20.2. Market Share Analysis of top Players 20.3. Market Presence Analysis 20.3.1. By Regional Footprint of Players 20.3.2. Drug Class Footprint by Players 20.3.3. Channel Footprint by Players 21. Competition Analysis 21.1. Competition Dashboard 21.2. Competition Benchmarking 21.3. Branding and Promotional Strategies, By Key Manufactures 21.4. Key Development Analysis 21.5. Competition Deep Dive 21.5.1. Johnson & Johnson 21.5.1.1. Overview 21.5.1.2. Drug Class Portfolio 21.5.1.3. Key Financials 21.5.1.4. Sales Footprint 21.5.1.5. SWOT Analysis 21.5.1.6. Strategy Overview 21.5.1.6.1. Marketing Strategies 21.5.1.6.2. Channel Strategies 21.5.1.6.3. Drug Class Strategies 21.5.2. Pfizer Inc. 21.5.3. Novartis AG 21.5.4. Glaxosmithkline Plc (GSK) 21.5.5. Sanofi 21.5.6. Bayer AG 21.5.7. Abbott Laboratories 21.5.8. Reckitt Benckiser Group Plc. 21.5.9. Teva Pharmaceutical Industries Ltd. 21.5.10. Thermo Fisher Scientific, Inc. 21.5.11. Haleon Group of Companies 21.5.12. Procter & Gamble 21.5.13. Sun Pharmaceutical Industries Ltd. 21.5.14. Amneal Pharmaceuticals LLC. 21.5.15. Cipla Limited 21.5.16. Purdue Pharmaceuticals L.P. 21.5.17. Hisamitsu Pharmaceutical Co., Inc. 21.5.18. Endo Pharmaceuticals, Inc. 21.5.19. Mallinckrodt Pharmaceuticals 21.5.20. Pure Source LLC 21.5.21. Teikoku Pharma 21.5.22. Himalaya Wellness Company 21.5.23. Troy Healthcare LLC 21.5.24. Advacare Pharma 21.5.25. Exzell Pharma 22. Assumptions and Acronyms Used 23. Research Methodology
Explore Healthcare Insights
View Reports
Topical Pain Relief Market
